Refractive profile of children treated with intravitreal bevacizumab for retinopathy of prematurity

被引:2
作者
Pawar, Neelam
Somyashree, D.
Meenakshi, R.
Maheshwari, Devendra
Mohideen, Syed
Uduman, Mohammed Sithiq
机构
[1] Aravind Eye Hosp, Pediat Ophthalmol & Squint Serv, Tirunelveli, Tamil Nadu, India
[2] Post Grad Inst Ophthalmol, Tirunelveli, Tamil Nadu, India
关键词
Intravitreal bevacizumab; laser; myopia; refractive errors; ROP; TYPE-1; RETINOPATHY; LASER PHOTOCOAGULATION; OUTCOMES; RANIBIZUMAB; ERROR;
D O I
10.4103/ijo.IJO_1209_22
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To study the refractive profile of children after they received intravitreal injection of bevacizumab for retinopathy of prematurity (ROP).Methods: The study was conducted at a tertiary eye care hospital in South India. ROP patients of more than 1 year of age, presenting to the Pediatric Ophthalmology Clinic and Retina Clinic and having history of treatment for type I ROP with intravitreal bevacizumab (IVB) or intravitreal bevacizumab and laser photocoagulation were included in the study. Cycloplegic refraction was done, and the refractive status was evaluated. The refractive status of age-matched, full-term children with uneventful perinatal and neonatal history was also recorded and compared to the study group.Results: Among 134 eyes of 67 study subjects, the major refractive error was myopia in 93 eyes (69.4%; spherical equivalent [SE] = -2.89 +/- 3.1, range = -11.5 to -0.5 D). There were 75 eyes (56%) with low-to-moderate myopia; high myopia was seen in 13.4%, emmetropia in 18.7%, and hypermetropia in 11.9% of eyes. The majority of them (87%) had with-the-rule (WTR) astigmatism. In 134 eyes, the SE was -1.78 +/- 3.2 (range = -11.5 to 4 D); the SE of the 75 eyes with low-to-moderate myopia was -1.53 +/- 1.2 (range = -0.50 to -5 D). In the control group, the majority had emmetropia (91.8%). There was no significant association between the age at which IVB had been injected and the development of refractive errors (P = 0.078). The prevalence of low-to-moderate myopia was more than high myopia in patients with zone I and zone II ROP before treatment (60.0% and 54.5%, respectively).Conclusion: Myopia was the major refractive error seen in post-IVB pediatric patients. WTR astigmatism was more commonly seen. The age at which IVB injection had been given had no effect on the development of refractive errors.
引用
收藏
页码:2561 / 2568
页数:8
相关论文
共 50 条
[41]   Intravitreal bevacizumab for retinopathy of prematurity in infants ineligible for laser therapy [J].
Hondur, Ahmet Murad ;
Cubuk, Mehmet Ozgur ;
Ozen Tunay, Zuhal ;
Atalay, Hatice Tuba ;
Ozdemir, Ozdemir ;
Petricli, Ikbal Seza ;
Gurelik, Ihsan Gokhan .
TURKISH JOURNAL OF MEDICAL SCIENCES, 2016, 46 (03) :764-768
[42]   Exudative retinopathy and detachment: A late reactivation of retinopathy of prematurity after intravitreal bevacizumab [J].
Ittiara, Shaun ;
Blair, Michael P. ;
Shapiro, Michael J. ;
Lichtenstein, Steven J. .
JOURNAL OF AAPOS, 2013, 17 (03) :323-325
[43]   Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity [J].
A. Şahin ;
Z. Gürsel-Özkurt ;
M. Şahin ;
F. M. Türkcü ;
A. Yıldırım ;
H. Yüksel .
Irish Journal of Medical Science (1971 -), 2018, 187 :417-421
[44]   Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity [J].
Karkhaneh, Reza ;
Khodabande, Alireza ;
Riazi-Eafahani, Mohammad ;
Roohipoor, Ramak ;
Ghassemi, Fariba ;
Imani, Marjan ;
Farahani, Afsar Dastjani ;
Adib, Nazanin Ebrahimi ;
Torabi, Hamidreza .
ACTA OPHTHALMOLOGICA, 2016, 94 (06) :E417-E420
[45]   Neurodevelopmental Outcomes Associated With Intravitreal Bevacizumab Injections for Retinopathy of Prematurity [J].
Webb, Alexandra R. .
ADVANCES IN NEONATAL CARE, 2022, 22 (02) :154-160
[46]   Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity [J].
Ghani, Muhammad Usman ;
Mehboob, Maria ;
Khans, Asma ;
Imran, Muhammad .
PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2018, 12 (02) :713-715
[47]   Postmortem vitreous bevacizumab levels of an infant treated for retinopathy of prematurity [J].
Hypes, Stephen ;
Nasser, Orwa ;
Hanna, Nancy ;
Lawhon, William ;
Bouhenni, Rachida ;
Hertle, Richard W. .
JOURNAL OF AAPOS, 2016, 20 (06) :537-539
[48]   Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age [J].
Chen, Yen-Chih ;
Chen, San-Ni ;
Yang, Benjamin Chi-Lan ;
Lee, Kun-Hsien ;
Chuang, Chih-Chun ;
Cheng, Chieh-Yin .
JOURNAL OF OPHTHALMOLOGY, 2018, 2018
[49]   A Review of Refractive Errors Post Anti-Vascular Endothelial Growth Factor Injection and Laser Photocoagulation Treatment for Retinopathy of Prematurity [J].
Wang, Amy T. ;
Gupta, Isha ;
Dai, Shuan .
JOURNAL OF CLINICAL MEDICINE, 2025, 14 (03)
[50]   Refractive, Visual and Retinal Outcomes after Intravitreal Ranibizumab Monotherapy for Retinopathy of Prematurity [J].
Alhassan, Nora Hassan ;
Abohaimed, Foziyah ;
Albalawi, Maram ;
Aldarwesh, Amal ;
Aldibasi, Omar ;
Hazzazi, Mohammed ;
Fahmy, Rania Medhat .
OPEN OPHTHALMOLOGY JOURNAL, 2023, 17